Article info

Download PDFPDF

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

Authors

  1. Correspondence to Professor Yannick Allanore, Rheumatology A, Hospital Cochin Rheumatology Institute, Paris 75014, France; yannick.allanore{at}cch.aphp.fr
View Full Text

Citation

Allanore Y, Wung P, Soubrane C On behalf of the Investigators, et al
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

Publication history

  • Received June 26, 2020
  • Revised August 10, 2020
  • Accepted August 11, 2020
  • First published September 22, 2020.
Online issue publication 
November 13, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.